CORPORATE Archivi - Kedrion Biopharma

Choose your country

Find in Kedrion

Fostering dialogue between industry and European institutions

May 29, 2026 | CORPORATE

€150 million investment to triple Kedrion’s production capacity: Italy’s “Plasma Valley” to treat rare diseases

May 11, 2026 | CORPORATE

FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion’s contribution in rare and ultra‑rare diseases

Jan 20, 2026 | CORPORATE

Kedrion receives US approval for new 10% intravenous Immunoglobulin, the result of Italian investment and know-How

Oct 08, 2025 | CORPORATE

A new standard in Social Responsibility: PAS 24000 achieved

Aug 01, 2025 | CORPORATE

Gender Equality: a commitment that starts with people

Jul 16, 2025 | CORPORATE

Kedrion supports the MAPPA project: an initiative to share the voices of patients with PIDs

Apr 28, 2025 | CORPORATE

2024 in review: achieving +10% growth and unveiling our new identity

Apr 14, 2025 | CORPORATE

The President and CEO of PPTA visits the Bolognana plant

Mar 11, 2024 | CORPORATE

The meeting was a valuable opportunity for Kedrion and PPTA to strengthen our ongoing partnership

Kedrion awarded national tender for Portuguese plasma manufacturing

Mar 02, 2023 | CORPORATE

First shipments of plasma from Porto and Lisbon were received in the beginning of February

For more information please contact: [email protected]

You are now leaving www.kedrion.it. Medical information including licensed uses may be different outside of Italy.

No